Common use of Consolidated Adjusted EBITDA Clause in Contracts

Consolidated Adjusted EBITDA. The Consolidated Adjusted EBITDA, as of the last day of each Test Period set forth below, to be less than the amount set forth below opposite such measurement date: Test Period Consolidated Adjusted EBITDA 4 Quarters ending September 30, 2019 $ 2,000,000 4 Quarters ending December 31, 2019 $ 4,000,000 4 Quarters ending March 31, 2020 $ 8,000,000 4 Quarters ending June 30, 2020 $ 14,000,000 4 Quarters ending September 30, 2020 $ 18,000,000

Consolidated Adjusted EBITDA. The Consolidated Adjusted EBITDA, as of the last day of each Test Period set forth below, to be less than the amount set forth below opposite such measurement date: date Test Period Consolidated Adjusted EBITDA 4 Quarters quarters ending March 31, 2022 $10,500,000 4 quarters ending June 30, 2022 $11,000,000 4 quarters ending September 30, 2019 $ 2,000,000 4 Quarters ending December 31, 2019 $ 4,000,000 4 Quarters ending March 31, 2020 $ 8,000,000 4 Quarters ending June 30, 2020 $ 14,000,000 4 Quarters ending September 30, 2020 $ 18,000,0002022 and each fiscal quarter thereafter $13,000,000

Consolidated Adjusted EBITDA. The Consolidated Adjusted EBITDA, as of the last day of each Test Period set forth below, to be less than the amount set forth below opposite such measurement date: Test Period Consolidated Adjusted EBITDA 4 Quarters quarters ending March 31, 2021 $10,000,000 4 quarters ending June 30, 2021 $10,000,000 4 quarters ending September 30, 2019 $ 2,000,000 2021 $10,500,000 4 Quarters quarters ending December 31, 2019 $ 4,000,000 2021 $10,500,000 4 Quarters quarters ending March 31, 2020 $ 8,000,000 2022 $10,500,000 4 Quarters quarters ending June 30, 2020 $ 14,000,000 2022 $11,000,000 4 Quarters quarters ending September 30, 2020 $ 18,000,0002022 $13,000,000

Consolidated Adjusted EBITDA. The Consolidated Adjusted EBITDA, as of the last day of each Test Period set forth below, to be less than the amount set forth below opposite such measurement date: Test Period Consolidated Adjusted EBITDA 4 Quarters quarters ending March 31, 2022 $10,500,000 4 quarters ending June 30, 2022 $11,000,000 4 quarters ending September 30, 2019 $ 2,000,000 2022 $13,000,000 4 Quarters quarters ending December 31, 2019 $ 4,000,000 4 Quarters ending March 31, 2020 $ 8,000,000 4 Quarters ending June 30, 2020 $ 14,000,000 4 Quarters ending September 30, 2020 $ 18,000,0002022 and each fiscal quarter thereafter $14,500,000

Consolidated Adjusted EBITDA. The Consolidated Adjusted EBITDA, as of the last day of each Test Period set forth below, to be less than the amount set forth below opposite such measurement date: Test Period Consolidated Adjusted EBITDA 4 Quarters quarters ending March 31, 2021 $10,000,000 4 quarters ending June 30, 2021 $10,000,000 4 quarters ending September 30, 2019 $ 2,000,000 2021 $10,500,000 4 Quarters quarters ending December 31, 2019 $ 4,000,000 2021 $10,500,000 4 Quarters quarters ending March 31, 2020 $ 8,000,000 2022 $10,500,000 4 Quarters quarters ending June 30, 2020 $ 14,000,000 2022 $11,000,000 4 Quarters quarters ending September 30, 2020 $ 18,000,0002022 $13,000,000 4 quarters ending December 31, 2022 $14,500,000

Consolidated Adjusted EBITDA. The Consolidated Adjusted EBITDA, as of the last day of each Test Period set forth below, to be less than the amount set forth below opposite such measurement date: Test Period Consolidated Adjusted EBITDA 4 Quarters quarters ending June 30, 2021 $ (3,122,500 ) 4 quarters ending September 30, 2019 2021 $ 2,000,000 10,500,000 4 Quarters quarters ending December 31, 2019 2021 $ 4,000,000 10,500,000 4 Quarters quarters ending March 31, 2020 2022 $ 8,000,000 10,500,000 4 Quarters quarters ending June 30, 2020 2022 $ 14,000,000 11,000,000 4 Quarters quarters ending September 30, 2020 2022 $ 18,000,00013,000,000 4 quarters ending December 31, 2022 $ 14,500,000 101

Consolidated Adjusted EBITDA. The Consolidated Adjusted EBITDA, as of the last day of each Test Period set forth below, to be less than the amount set forth below opposite such measurement date: Test Period Consolidated Adjusted EBITDA 4 Quarters ending September 30, 2019 $ 2,000,000 3,000,000 4 Quarters ending December 31, 2019 $ 4,000,000 5,000,000 4 Quarters ending March 31, 2020 $ 8,000,000 10,000,000 4 Quarters ending June 30, 2020 $ 14,000,000 16,000,000 4 Quarters ending September 30, 2020 $ 18,000,00020,000,000

Consolidated Adjusted EBITDA. The Consolidated Adjusted EBITDA, as of the last day of each Test Period set forth below, to be less than the amount set forth below opposite such measurement date: date Test Period Consolidated Adjusted EBITDA 4 Quarters quarters ending June 30, 2021 $ (3,122,500 ) 4 quarters ending September 30, 2019 2021 $ 2,000,000 10,500,000 4 Quarters quarters ending December 31, 2019 2021 $ 4,000,000 10,500,000 4 Quarters quarters ending March 31, 2020 2022 $ 8,000,000 10,500,000 4 Quarters quarters ending June 30, 2020 2022 $ 14,000,000 11,000,000 4 Quarters quarters ending September 30, 2020 2022 $ 18,000,00013,000,000